Earlier today we announced that two health insurers in Switzerland had agreed to reimburse SCENESSE® (afamelanotide) for the rare disease erythropoietic protoporphyria (EPP). While this is an encouraging step forward for the program and for Swiss patients, I felt it appropriate to take a moment to discuss the important role that Switzerland has played, and continues to play, in our EPP program.
In 2006 Clinuvel announced that it would commence a new clinical trial program focused on an unknown disease in a small open label study. At the time I noted that our aim was to “provide a prophylactic treatment for [a] debilitating and incurable skin disorder”. (more…)
In a letter published this week in the 
We recently invited Richard Roosenboom to share his experiences as a parent of a child with a rare disease. In the coming weeks we will publish part of the Roosenboom’s story in a four post series. You can read the first post here: 
Myth 4: I need lots of sun exposure to create vitamin D
Those who have taken an interest in Clinuvel will have learned with joy that, on Monday February 6th, the company announced its 
There are a number of misconceptions about the interaction between sunlight and skin. In this two part post we look at what we think are the top five most common sun and skin myths.
Young adults are the age group most likely to seek a tan, with research showing that people under the age of 29 – particularly women – are tanning most frequently, both in the sun and under solariums. Aside from the well-recognised risks of skin cancer, there is another consequence of this increased exposure to ultraviolet (UV) radiation of which many teens are not aware – photoaging. In short, all this UV exposure over time makes skin look older. 
